U.S. FDA Approves ALK’s RagwitekAdolescents, Approvals, Children, FDA, New Indications, Ragweed PollenThe U.S. Food and Drug Administration approved ALK Inc.’s Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use for the treatment of short ragweed pollen-induced allergic rhinitis in persons ages 5 through 65 years old. Read more April 19, 2021/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2021/04/ALK_Logo.jpg 54 200 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2021-04-19 08:00:302021-04-20 12:57:50U.S. FDA Approves ALK’s Ragwitek